Eli Lilly and Company
The deal grants Lilly exclusive global rights to use Insilico's Pharma.AI platform for drug discovery and development across multiple therapeutic areas.
The San Francisco-based lab will house Eli Lilly experts in biology, science and medicine alongside NVIDIA AI model builders and engineers.
TrumpRx will offer Novo Nordisk's Ozempic and Wegovy for $350 and Eli Lilly and Company's Zepbound and orforglipron, if approved by the FDA, for $346.
Eli Lilly and Company says the partnership will result in the development of the most powerful supercomputer owned by a pharmaceutical company.
The hub expands the company's research and development footprint in the region and hastens the development of AI-powered digital health technologies.
The collaboration will leverage Genetic Leap's RNA-targeted AI platform to create genetic medicines against selected targets.
Also: Sutter Health and Aetna's joint venture partners with house call startup Heal; SideKickHealth announces strategic partnership with Bayer.
These data provide a proof of concept that Apple products and other consumer devices can play a role in monitoring or identifying disease symptoms.
Pharma companies also continued to explore the promises of digital therapeutics.
Onduo, Livongo, Abbott and others also shared news at the show.